← Timeline

BRK.B · The Fortress Unlocks — Multi-Analyst Outlook 2026–2031

BRK.B · Oct 19, 2026 · Analysis · Gemini

⇆ Compare
BRK.B$532.02▲ 14.7% off Apr ’26 low · 1.1% off 52-wk high52-wk $464.01 – $537.74As of Oct 19, 2026

Independent analysis of BRK.B — “BRK.B · The Fortress Unlocks — Multi-Analyst Outlook 2026–2031”, published Oct 19, 2026 as part of Stock Timelines, a running journal of independent equity research. Featuring consensus target $542.5, projected target $815 (5y).

Key Research Takeaways: BRK.B · The Fortress Unlocks — Multi-Analyst Outlook 2026–2031

Tickers Analyzed
BRK.B
Consensus Price Target
$542.5
Projected Price Target (5y)
$815
Spot Price at Analysis
$532.02 (▲ 14.7% off Apr ’26 low · 1.1% off 52-wk high)
52-Week Range
$464.01 - $537.74
Publication Date
Oct 19, 2026
Research Provider
Gemini
01 · Equity deep-dive — Omaha ledger & synthesized analyst desk
BRK.B
$532.02 ▲ 14.7% off Apr ’26 low · 1.1% off 52-wk high
NYSE · DIVERSIFIED FINANCIALS & INDUSTRIALSMKT CAP ≈ $1.14T52-WK $464.01 – $537.74AS OF OCT 19, 2026

The architect stepped back. The $365 billion vault is finally unlocking.

After 14 consecutive quarters of net equity sales under Warren Buffett, new CEO Greg Abel has pivoted Omaha from capital hoarding to disciplined offense — deploying $9.7B into OxyChem, $6.8B into Taylor Morrison, $10B into Alphabet, $930M into Bending Spoons, and re-igniting $4.5B of quarterly buybacks while operating earnings compound +16% YoY. Five analyst lenses, three scenarios, four time horizons.

Liquid Vault (Jun 30, ’26)$364.7B ($324.9B T-Bills)
Perpetual Insurance Float$177.5B (87.1% FY25 comb. ratio)
13F / Fair-Value Equities$323.8B (Net buyer in Q2 ’26)
2026 Capital Deployed~$32.0B+ (OxyChem · TMHC · GOOGL · Buybacks)
Shareholders’ Equity$750.2B (1.53× P/B · 13.4× GAAP P/E)
The verdict · TL;DR
One question decides the stock: can Greg Abel convert $364.7B of 4%-yielding Treasury bills into 12%+ operating compounders without losing the “Buffett premium”? Q2 2026 operating earnings jumped 16.3% YoY to $12.98B ($6.02/sh vs. $5.00 est.), industrial and energy units surged 24–27%, and Berkshire turned a net buyer of stocks for the first time in 15 quarters. The floor is fortress-grade; the upside hinges on reinvestment velocity vs. falling short-term interest rates.
5-yr · prob-weighted
$778
+46% vs $532.02
52-week playback · where the tape sits ▶ Pressing the upper band (10-day Oct streak)
$532.02 · Oct 19, 2026 Street consensus $542.50 (+2%) · M★ Fair Value $587 (+10%)
$464.01 · 52-wk low · Apr 16, ’26 $537.74 · 52-wk high · Aug 10, ’26 (ATH $542.07 · May ’25)
Price history + cone of outcomes · 2024 → 2031
HISTORICALBULLBASEBEARPROB-WTD
$1,100$940$780 $620$460$300 202420252026 202720282029 20302031 $542 ATH · May ’25 $464 · Apr ’26 low $778 $568$620$680 $1,060 $815 $420 TODAY · $532.02

Gray line = BRK.B actual price history from early 2024 ($398) through the May 2, 2025 pre-handover peak ($542.07), the April 16, 2026 succession trough ($464.01), the August 10, 2026 Q2 earnings breakout ($537.74), into October 19, 2026 ($532.02); colored paths = synthesized scenario midpoints forward, probability-weighted (base 50% · bull 25% · bear 25%). Sell-side 12-month targets span $490 (Hold) to $604 (UBS Buy), with Morningstar Fair Value at $587.23.

Re-weight the scenarios

Those probabilities are a judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of the scenario cards all update live.

25% bear 50% base 25% bull
Blended 5-yr expected $778 +46% vs $532.02
+16.3%
Q2’26 Operating Earnings ($12.98B)
+20.4%
Q2 Operating EPS Beat ($6.02 vs $5.00)
$364.7B
Cash & U.S. T-Bills Vault
$177.5B
Perpetual Insurance Float
$4.53B
Q2’26 Share Buybacks (19× Q1 pace)
+$11.6B
H1’26 Net Equity Purchases ($39.4B bought)
1.53×
Price / Book ($750.2B Equity)
87.1%
P&C Combined Ratio (FY25)
02 · The panel — five independent desks on the post-Buffett machine

Five analyst lenses, five answers

Does Berkshire deserve a re-rating as Greg Abel unlocks its $364.7B war chest, or does falling short-term interest income cap the multiple? Each synthesized desk below runs an independent valuation framework.

Growth / Capital Deployment PMHIGH CONVICTION

The Unlocked Vault

For 14 quarters Berkshire sat on its hands as cash swelled toward $380B. In H1 2026, Greg Abel flipped the switch: closing $9.7B OxyChem, $6.8B Taylor Morrison, committing $10B to Alphabet, buying $930M of Bending Spoons, and buying back $4.53B of stock in Q2 alone. Swapping 4% T-bills for 12%+ ROIC operating assets adds $8–10B in annual earnings power.

  • MSR operating profit jumped +24.1% YoY in Q2’26 ($4.47B); BHE surged +26.9% ($891M).
  • BHE utility capex is a direct tollbooth on AI data-center power demand across the Western grid.
  • Aggressive buybacks ($4.8B H1’26) shrink Class A equivalent float (down to 1,431,693 shares).
12-MO TARGET $604 · ~1.65× fwd book / 23.7× ’27E Op EPS
Value / Look-Through FCF AnalystHIGH CONVICTION

The Sum-of-the-Parts Anchor

Headline 22× operating P/E is an optical illusion because it penalizes Berkshire for holding $364.7B in low-yielding cash and only counts dividends—not retained earnings—from its $323.8B equity portfolio. Strip out ex-float net cash and credit look-through retained earnings from Apple, AmEx, and Alphabet, and you are paying ~15.8× for world-class rail, energy, and industrial franchises.

  • Book value per share compounded at 18.1% CAGR (1965–2025) vs. 10.5% for the S&P 500.
  • $177.5B of zero-cost insurance float funds half the equity portfolio for free.
  • Morningstar intrinsic fair value stands at $587.23 (+10.4% upside from today).
12-MO TARGET $587 · 1.58× fwd book / intrinsic SOTP
Moat / Competitive-Strategy AnalystMEDIUM-HIGH CONVICTION

The Permanent Capital Moat

With Howard Buffett installed as non-executive Chairman in September 2026 and Greg Abel running operations, the governance architecture is locked in. No private-equity firm or activist can replicate permanent capital that never faces redemptions, regulatory statutory surplus of $333B, and a railroad + interstate grid network with infinite replacement cost.

  • P&C combined ratio of 87.1% beats the 20-year average (92.2%) by over 500 bps.
  • BNSF (+6.3% Q2 profit to $1.56B) operates an irreplaceable transcontinental freight duopoly.
  • Zero forced selling during macro drawdowns creates structural counter-cyclical optionality.
12-MO TARGET $565 · ~1.55× fwd book + moat durability
Quant / Technical & Macro StrategistMEDIUM CONVICTION

The Rate-Cut & Multiple Ceiling

BRK.B just logged a 10-day winning streak in mid-October 2026—its longest since 2018—pushing RSI(14) to the 79th percentile (62.7) and price to 1.53× book vs. a 10-year median of 1.42×. Meanwhile, the Fed's rate-cutting cycle is already biting: Q2’26 insurance investment income fell 9.1% YoY ($3.06B vs. $3.37B). Every 100 bps drop in T-bill yields clips ~$3.2B pre-tax from the vault.

  • Trades above 50-day EMA ($508.52) and 200-day SMA ($493.56), near $537.74 resistance.
  • 1-year trailing return (+5.90%) has lagged the US Market Index (+16.80%) by ~10.9 pts.
  • T-bill rollover drag offsets roughly half of industrial operating profit growth in 2027E.
12-MO TARGET $542 · in line with Street median ($542.50)
Bear / Disruption & Deals SkepticMEDIUM CONVICTION

The Deal-Quality & Cycle Bear

Buffett hoarded cash because bargains didn’t exist at $1.14T scale; Abel is spending into a slowing economy. Paying $72.50/share ($6.8B) for homebuilder Taylor Morrison and doubling down on Lennar right as U.S. payrolls shed jobs, buying OxyChem ($9.7B) into a commodity trough, and chasing tech via Alphabet ($10B) and Bending Spoons ($930M) smells like style drift just as GEICO’s loss ratio worsens by 480 bps YoY.

  • GEICO Q2’26 loss ratio jumped to 76.6% (vs. 71.8% Q2’25); underwriting profit fell 13.1% YoY.
  • FY25 took $8.26B in impairments on Kraft Heinz and Occidental — acquisition scars remain real.
  • A reversion to Berkshire’s historical 1.30× P/B multiple prices the stock near $475.
12-MO TARGET $485 · 1.32× fwd book / P&C & rate normalization
Q2 2026 Operating Ledger (10-Q · Aug 8, ’26) Q2 2026 Q2 2025 YoY Chg H1 2026 H1 2025 Share of Q2 Op Profit
Manufacturing, Service & Retailing (incl. OxyChem) $4,470M $3,601M +24.1% $7,669M $6,661M 34.4%
Insurance — Investment Income $3,059M $3,367M −9.1% $5,738M $6,260M 23.6%
Insurance — Underwriting (GEICO, Primary, Reins.) $1,731M $1,992M −13.1% $3,448M $3,328M 13.3%
BNSF Railway ($6,601M Q2 rev) $1,558M $1,466M +6.3% $2,935M $2,680M 12.0%
Berkshire Hathaway Energy (BHE) $891M $702M +26.9% $2,005M $1,799M 6.9%
Other (incl. +$326M non-USD debt FX gain) $1,274M $32M n/m $2,534M $73M 9.8%
Total Operating Earnings (Non-GAAP) $12,983M $11,160M +16.3% $24,329M $20,801M 100.0%
GAAP Net Earnings (incl. $12,684M Q2 inv. gains) $25,667M $12,370M +107.5% $35,773M $16,973M $11.91 / B-sh (Q2)
03 · Wall Street's read

Wall Street 12-month price targets & fair values

Unlike hyper-covered megacap tech, Berkshire is sparsely covered by traditional sell-side desks. Below are published institutional targets and fair-value models sorted low to high against today's $532.02.

Street Median ≈ $542.50 (+2.0%) · Institutional Fair-Value Range $490–$604
BUY / UNDERVALUEDHOLD / MARKET PERFORMCAUTIOUS / SELL
Autonomous Research $490 Keefe, Bruyette & Woods $525 TD Cowen $530 MarketBeat Consensus $542.50 CFRA Research $555 Argus Research $570 Morningstar / InvestingPro $587 UBS Equities $604 TODAY · $532.02

Because Berkshire holds no quarterly earnings calls and issues no guidance, traditional broker coverage is thin (MarketBeat tracks 1 Buy and 2 Holds with a $542.50 mean target). However, specialist insurance/conglomerate desks at UBS ($604 Buy, raised post-Q2’26 beat) and intrinsic-value models at Morningstar/InvestingPro (~$587 Undervalued) see 10–14% 12-month upside as Abel’s capital deployment accretes earnings per share.

04 · Price scenarios — 1 / 2 / 3 / 5 years

Where the ledger compounds

Synthesized scenario midpoints (mid-year). Returns shown vs. today's $532.02. These are illustrative frameworks, not predictions with certainty — five-year outcomes depend on whether active capital deployment outpaces the drag from lower short-term Treasury yields.

1 Year

Mid-2027
Bull$625+17%
Base$568+7%
Bear$460−14%
Prob-wtd$555+4%

2 Years

Mid-2028
Bull$720+35%
Base$620+17%
Bear$445−16%
Prob-wtd$601+13%

3 Years

Mid-2029
Bull$830+56%
Base$680+28%
Bear$435−18%
Prob-wtd$656+23%

5 Years

Mid-2031
Bull$1,060+99%
Base$815+53%
Bear$420−21%
Prob-wtd$778+46%
▸ Bull case — show the assumptions & math
Greg Abel deploys $180–220B of excess cash over 2026–2030 into accretive industrial, energy, and tech compounders at 12%+ ROIC while repurchasing ~2.5–3.0% of shares annually. BHE earns premium regulated returns building transmission & power generation for AI data centers, P&C combined ratios stay sub-90%, and look-through equity earnings compound at 12%/yr.
2031E Operating EPS ≈ $41.50 × 25.5× exit multiple (≈ 1.75× 2031E Book Value of ~$605/sh) → $1,060 · 5-yr CAGR ≈ +14.8%/yr
▸ Base case — show the assumptions & math
Operating earnings compound at ~9.5% per share annually: OxyChem, Taylor Morrison, BNSF, and BHE expand operating profit by 8–10%/yr, offsetting a normalization in T-bill yields toward 3.25% and a ~91% P&C combined ratio. Share repurchases run ~$14–18B/yr (~1.5% float reduction), and the P/B multiple holds steady near today's ~1.55×.
2031E Operating EPS ≈ $37.00 × 22.0× exit multiple (≈ 1.55× 2031E Book Value of ~$526/sh) → $815 · 5-yr CAGR ≈ +8.9%/yr
▸ Bear case — show the assumptions & math
Fed rate cuts slash insurance investment income by $6B+ annually, GEICO & reinsurance enter a soft P&C pricing cycle with elevated catastrophe losses, housing and chemical acquisitions (Taylor Morrison, Lennar, OxyChem) suffer a cyclical downturn, and institutional holders demand a conglomerate discount without Warren Buffett at the helm.
2031E Operating EPS stagnates near ~$29.00 × 14.5× de-rated multiple (≈ 1.12× depressed Book Value) → $420 · 5-yr CAGR ≈ −4.6%/yr
05 · Follow the cash

Revenue, capex, free cash flow & debt ($B)

Consolidated cash generation across insurance, rail, energy, and manufacturing (2023–2026E). Note how Berkshire invests ~$19–23B annually in heavy physical capex (BHE grid & BNSF track) while still throwing off $24–30B of free cash flow.

Annual revenue, capex, FCF & total debt · 2023 → 2026E ($B)
REVENUECAPEXFREE CASH FLOWTOTAL DEBT
$0B $105B $210B $315B $420B 2023202420252026E $365B$371B$371B$394B $30B$12B*$25B$27B

*In FY 2024, reported operating cash flow ($30.6B) and FCF ($11.6B) were temporarily depressed by $28.5B of cash income taxes paid on massive realized Apple stock gains; in FY 2025, operating cash flow rebounded +50.3% to $46.0B and FCF more than doubled to $25.0B (TTM Jun ’26 OCF = $46.6B, Capex = $22.4B, FCF = $24.2B). Total consolidated debt (~$128.6B) is predominantly non-recourse BNSF and BHE utility debt, dwarfed by $364.7B of cash and T-bills (net cash ≈ +$236B).

06 · Earnings power

Operating EPS path underpinning the targets ($)

Per Warren Buffett's and Greg Abel's longstanding rule, GAAP net income swings wildly on unrealized equity mark-to-market gains ($25.7B in Q2’26 alone). The scenario targets are built on clean after-tax Operating EPS per Class B equivalent share.

Operating EPS per Class B share · reported vs. estimated, 2024 → 2031E
REPORTEDBASE ESTIMATE
$0$10$20$30$40 202420252026E2027E2028E2029E2030E2031E $21.95 $20.62 $23.40 $25.50 $27.90 $30.60 $33.60 $37.00

After dipping 6% in FY25 ($44.49B vs. $47.44B in FY24) on Tough P&C comparisons, Operating EPS has inflected sharply in 2026 (+17.0% YoY in H1’26 to $24.33B, or ~$11.34/B-share in just six months). Our base case models Operating EPS compounding ~9.5%/yr from $23.40 in 2026E to $37.00 by 2031E as operating acquisitions (OxyChem, Taylor Morrison) and steady share buybacks (~1.5%/yr) overpower lower T-bill interest income. At a steady 22.0× exit multiple, $37.00 yields the $815 base-case 5-year target.

07 · Growth scorecard

The real-economy engine is accelerating

Q2 2026 & latest reported YoY growth across Berkshire's operating pillars and capital-deployment frontier — notice how industrial, energy, and capital deployment surged even as insurance float income cooled.

Year-over-year growth by metric · Q2 2026 / H1 2026 (10-Q)
CORE OPERATING PILLARSFRONTIER & CAPITAL DEPLOYMENT
H1 Insurance underwriting +3.6% Q2 Consolidated revenue +5.5% BNSF Railway Q2 profit +6.3% Total Q2 operating earnings +16.3% Mfg, Service & Retailing Q2 +24.1% BH Energy (BHE) Q2 profit +26.9% Q2 GAAP Net Earnings +107.5% H1 Gross Equity Purchases +455% ($39.4B vs $7.1B)

While Q2 insurance investment income dipped 9.1% YoY on lower short-term yields, Berkshire's industrial and energy core is firing on all cylinders: Manufacturing, Service & Retailing jumped +24.1% YoY (bolstered by OxyChem), BHE climbed +26.9% YoY, and gross equity purchases surged more than 5.5× ($39.4B in H1’26 vs. $7.1B in H1’25) alongside $4.53B of Q2 share buybacks.

08 · The debate

Bull vs. Bear

The entire valuation argument compresses into one disagreement: is Greg Abel unlocking a generational compounding wave from Berkshire's $364.7B vault, or deploying into a late-cycle slowdown while T-bill income rolls over?

▲ THE BULL CASE

  • The $364.7B cash drag is turning into an earnings engine. Reallocating $30B+ in H1 2026 alone (OxyChem $9.7B, Taylor Morrison $6.8B, Alphabet $10B, Bending Spoons $930M) swaps ~4% T-bill paper for double-digit operating and equity compounders.
  • Operating earnings momentum is accelerating. Q2 2026 operating profit rose +16.3% YoY to $12.98B ($6.02/sh vs. $5.00 est.), led by Manufacturing/Service/Retailing (+24.1%) and Berkshire Hathaway Energy (+26.9%).
  • Buybacks are back in size. Abel repurchased $4.53B of stock in Q2 2026 (nearly 20× Q1’s $235M pace and reversing FY25’s zero-buyback pause), signaling management sees intrinsic value well above $530.
  • $177.5B of zero-cost perpetual float. Insurance float grew another $1.5B in H1 2026 and achieved an exceptional 87.1% P&C combined ratio in FY25 — structural leverage no competitor can match.
  • AI power & North American infrastructure tollbooth. BHE (~24,000 employees, multi-decade regulated grid capex) and BNSF ($6.6B Q2 revenue) sit directly in the path of U.S. industrial reshoring and data-center power demand.
  • Seamless governance transition. With Greg Abel as CEO, Howard Buffett named Chairman in Sept 2026, and Warren Buffett as Chairman Emeritus, the culture of decentralized permanence is intact.

▼ THE BEAR CASE

  • Short-term rate cuts directly erode float income. With $324.9B parked in U.S. Treasury Bills at June 30, 2026, every 100 bps of Fed easing strips ~$3.2B in pre-tax annual interest income — Q2’26 insurance investment income already fell 9.1% YoY.
  • Auto & P&C underwriting is peaking. GEICO’s Q2 2026 loss ratio rose 480 bps YoY to 76.6% (from 71.8% in Q2’25), pulling Q2 insurance underwriting profit down 13.1% YoY to $1.73B.
  • M&A timing and price-discipline risk. Buying Taylor Morrison ($6.8B at a hefty $72.50/sh premium), doubling down on Lennar (25.9M shares), and buying OxyChem ($9.7B) increases cyclical exposure to housing and petrochemicals just as U.S. job growth wobbles.
  • Investment bench turnover & tech style drift. Following Todd Combs’ departure and Buffett stepping back, multi-billion commitments to Alphabet ($10B) and European tech roll-up Bending Spoons ($930M) mark a departure from classic Buffett value moats.
  • Write-down scars and conglomerate scale drag. FY25 absorbed $8.26B in other-than-temporary impairments on Kraft Heinz and Occidental; moving the needle on a $1.14T market cap requires $50B+ elephant deals that carry massive execution risk.
  • Valuation sits near the top of its historical band. At 1.53× book value and a 79th-percentile RSI after a 10-day October winning streak, any fading of the “Buffett premium” toward 1.30× book implies ~15% downside.
09 · Risk map

Risk map — likelihood × impact

Nine structural risks mapped across a 3–5 year horizon. The highest-probability pressure point is T-bill yield compression in the upper-right quadrant, while mega-catastrophe and post-Buffett multiple de-rating sit one row down.

Low impact
Medium impact
High impact
Likely
  • FX debt & mark-to-market noise
  • GEICO loss-ratio creep
  • BNSF fuel & labor inflation
  • Fed rate-cut T-bill drag
Possible
  • Housing & chemical M&A cyclicality
  • BHE wildfire & utility liability
  • Post-Buffett multiple de-rating
  • Equity portfolio concentration
Tail
  • 1-in-100 yr super-catastrophe

Fed rate-cut T-bill drag

Likely × High

Each 100 bps drop in short-term Treasury yields cuts ~$3.2B of pre-tax interest income off the $324.9B T-bill hoard before Abel can fully redeploy it.

Post-Buffett multiple de-rating

Possible × High

If an early Abel acquisition stumbles, institutional investors could compress BRK.B from 1.53× P/B toward a 1.25–1.30× conglomerate multiple.

Equity portfolio concentration

Possible × High

Top holdings (Apple, AmEx, BofA, Coca-Cola, Chevron, Alphabet) dominate the $323.8B stock book; a tech or financial drawdown hits book value directly.

GEICO loss-ratio creep

Likely × Medium

GEICO's Q2’26 loss ratio rose 480 bps YoY to 76.6% as it chased policy growth against Progressive; sustained auto-claim inflation squeezes underwriting margins.

BNSF fuel & labor inflation

Likely × Medium

Q2’26 BNSF fuel expense jumped 68% YoY ($1,173M vs. $698M); oil spikes in the Strait of Hormuz or rail union wage resets cap operating ratio gains.

1-in-100 yr super-catastrophe

Tail × High

A $150B+ industry mega-quake or cyber/hurricane event tests BH Reinsurance and statutory surplus — low odds, but a $10–15B single-quarter hit.

Housing & chemical M&A cyclicality

Possible × Medium

OxyChem ($9.7B), Taylor Morrison ($6.8B), and Lennar (25.9M shares) increase exposure to U.S. housing starts and industrial chemical spreads.

BHE wildfire & utility liability

Possible × Medium

Inverse-condemnation wildfire litigation in Western states threatens regulated utility ROE and could strand BHE’s multi-billion grid capex.

FX debt & mark-to-market noise

Likely × Low

Yen/Euro debt revaluations ($326M gain in Q2’26 vs. $877M loss in Q2’25) and GAAP equity swings create headline volatility for casual observers.

10 · Plain-language glossary

The Omaha jargon, decoded

Hover the dotted terms in the metrics, or scan the desk's working definitions for analyzing Berkshire's unique accounting.

Operating earnings
Berkshire's preferred profit gauge ($12.98B in Q2’26; $44.49B in FY25): net income from wholly owned businesses plus dividends/interest, stripping out volatile stock-market capital gains and impairments.
Insurance float
Policyholder premiums collected up front before claims are paid out ($177.5B at June 30, 2026). So long as underwriting breaks even or better, float is better-than-free permanent capital.
Combined ratio
Incurred insurance losses + underwriting expenses ÷ earned premiums. Below 100% means an underwriting profit; Berkshire's P&C units posted 87.1% in FY25.
Loss ratio
The slice of earned premiums paid out in claims alone. GEICO's loss ratio ticked up to 76.6% in Q2’26 from 71.8% in Q2’25 as it pivoted back to customer growth.
Look-through earnings
Operating earnings plus Berkshire's proportional share of the undistributed retained earnings of its $323.8B equity portfolio (Apple, AmEx, Alphabet, etc.), minus hypothetical taxes.
Class A equivalent share
One BRK.A share equals 1,500 BRK.B shares in economic interest. At June 30, 2026, Berkshire had 1,431,693 Class A equivalent shares (~2.148B Class B equivalent shares).
Price / Book (P/B)
Market cap ($1.14T) ÷ shareholders' equity ($750.2B) = 1.53×. Historically Berkshire's primary valuation anchor, oscillating between 1.20× (cheap) and 1.60× (rich).
Statutory surplus
Capital held by insurance subsidiaries above regulatory minimums (~$333B for Berkshire's U.S. insurers at YE 2025), allowing up to $31B in annual dividends to Omaha without prior approval.
NOT FINANCIAL ADVICE

Sources & method: Berkshire Hathaway Inc. Q2 2026 Form 10-Q and earnings release (August 8–10, 2026), Q1 2026 Form 10-Q, FY 2025 Annual Report / Form 10-K (February 28, 2026), SEC Form 13F-HR (period ended June 30, 2026), Occidental Petroleum / OxyChem closing Form 8-K (January 2, 2026), Taylor Morrison completion release (July 24, 2026), Morningstar, UBS, and MarketBeat consensus data, all verified as of October 19, 2026 (next earnings release scheduled for November 7, 2026). The five "analyst lenses" are synthesized institutional frameworks — not real individuals or official firm ratings. Scenario prices are illustrative midpoints, not forecasts; actual outcomes can fall outside the cone. Not financial advice — do your own research and consider consulting a licensed financial advisor.